Skip to main content
British Medical Journal logoLink to British Medical Journal
. 1978 Mar 11;1(6113):610–612. doi: 10.1136/bmj.1.6113.610

High incidence of vincristine-induced neuropathy in lymphomas.

S M Watkins, J P Griffin
PMCID: PMC1603389  PMID: 630255

Abstract

The incidence of vincristine-induced neuropathy was studied in 60 unselected patients, of whom 23 had lymphoma and 37 had other malignant disease. All were treated with vincristine combined with other cytotoxic agents. Fourteen of the patients with lymphoma (61%) developed neuropathy compared with five patients with leukaemia or non-lymphoid cancer (14%), even though all patients received comparable doses of vincristine. The difference between the two groups in the incidence of neuropathy was highly significant. Of the patients who developed neuropathy, 17 did so within the first three months of treatment and seven in the first month. Patients with lymphoma who are receiving vincristine should be observed carfully for symptoms and signs of neuropathy. Vincristine should be withdrawn if progressive neurotoxicity develops.

Full text

PDF
610

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Casey E. B., Jellife A. M., Le Quesne P. M., Millett Y. L. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96(1):69–86. doi: 10.1093/brain/96.1.69. [DOI] [PubMed] [Google Scholar]
  2. Croft P. B., Wilkinson M. The incidence of carcinomatous neuromyopathy in patients with various types of carcinoma. Brain. 1965 Sep;88(3):427–434. doi: 10.1093/brain/88.3.427. [DOI] [PubMed] [Google Scholar]
  3. Hardisty R. M., McElwain T. J., Darby C. W. Vincristine and prednisone for the induction of remissions in acute childhood leukaemia. Br Med J. 1969 Jun 14;2(5658):662–665. doi: 10.1136/bmj.2.5658.662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Roeser H. P., Hocker G. A., Kynaston B., Roberts S. J., Whitaker S. V. Advanced non-Hodgkins' lymphomas: response to treatment with combination chemotherapy and factors influencing prognosis. Br J Haematol. 1975 Jun;30(2):233–247. doi: 10.1111/j.1365-2141.1975.tb00537.x. [DOI] [PubMed] [Google Scholar]
  5. SHAW R. K., BRUNER J. A. CLINICAL EVALUATION OF VINCRISTINE (NSC-67574). Cancer Chemother Rep. 1964 Nov;42:45–48. [PubMed] [Google Scholar]
  6. Sandler S. G., Tobin W., Henderson E. S. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology. 1969 Apr;19(4):367–374. doi: 10.1212/wnl.19.4.367. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES